A team from Cleveland Clinic (OH, USA) has identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
In this interview, Marika tells us about her research on tissue clearing and imaging, including her opinion on what the biggest ‘hot topic’ in neurodegeneration is.
Hannah Churchill reports on the Alzheimer’s Society Annual Conference (22–23 May, London, UK), including preventative risk factors, technology and dementia, as well as drug repurposing.
A recent study has reported that long-term consumption of caffeine has negative effects for Alzheimer’s disease, potentially worsening the neuropsychiatric symptoms in those affected by the disorder.
Rebecca Gabriele (KCL) reports on Day 2 of the ARUK Conference, including metabolism, neurodegeneration, tau, and insights into dementias from other diseases.
Scientists reveal that a new link between diminished input from dopamine-firing cells and the ability to form new memories could be crucial in detecting the earliest signs of Alzheimer’s disease.
In this editorial from Biomarkers in Medicine, discover how axonal transporter proteins may be utilized as biomarkers for a variety of neurological disorders.
Ocrelizumab has been licensed by EU regulators as a therapy for multiple sclerosis, the first ever drug to be approved for the primary progressive form of the disease.
Disturbance to nuclear transport caused by protein aggregation has been implicated in the pathology of ALS and FTD.